In the last trading session, 1.92 million Emergent Biosolutions Inc (NYSE:EBS) shares changed hands as the company’s beta touched 2.07. With the company’s per share price at $5.49 changed hands at $0.12 or 2.23% during last session, the market valuation stood at $298.31M. EBS’s last price was a discount, traded about -175.05% off its 52-week high of $15.10. The share price had its 52-week low at $1.82, which suggests the last value was 66.85% up since then. When we look at Emergent Biosolutions Inc’s average trading volume, we note the 10-day average is 1.0 million shares, with the 3-month average coming to 1.20 million.
Analysts gave the Emergent Biosolutions Inc (EBS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EBS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS was in green as seen at the end of in last trading. With action 18.83%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -42.57%, with the 5-day performance at 18.83% in the green. However, in the 30-day time frame, Emergent Biosolutions Inc (NYSE:EBS) is 6.19% up. Looking at the short shares, we see there were 9.02 million shares sold at short interest cover period of 7.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 51.5, meaning bulls need an upside of 89.34% from its current market value. According to analyst projections, EBS’s forecast low is 38 with 65 as the target high. To hit the forecast high, the stock’s price needs a -1083.97% plunge from its current level, while the stock would need to soar -592.17% for it to hit the projected low.
The 2025 estimates are for Emergent Biosolutions Inc earnings to increase by 426.09%.
EBS Dividends
Emergent Biosolutions Inc is expected to release its next quarterly earnings report on 2025-Mar-02.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.28% of Emergent Biosolutions Inc shares while 63.89% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 65.38%. There are 63.89% institutions holding the Emergent Biosolutions Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.2992% of the shares, roughly 3.84 million EBS shares worth $26.18 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.97% or 3.67 million shares worth $25.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were American Century ETF Trust-Avantis U.S. Small Cap Value ETF and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . With 1.94 shares estimated at $10.63 million under it, the former controlled 3.56% of total outstanding shares. On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF held about 2.83% of the shares, roughly 1.54 shares worth around $8.44 million.
